• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

达托霉素(LY 146032)与四种对照抗生素单独及联合使用时,对庆大霉素敏感和高水平庆大霉素耐药肠球菌的体外抑制和杀菌活性比较。

Comparison of in vitro inhibitory and bactericidal activities of daptomycin (LY 146032) and four reference antibiotics, singly and in combination, against gentamicin-susceptible and high-level-gentamicin-resistant enterococci.

作者信息

Louie A, Baltch A L, Ritz W J, Smith R P, Asperilla M

机构信息

Department of Medicine, Samuel S. Stratton Department of Veterans Affairs Medical Center, Albany, N.Y. 12208.

出版信息

Chemotherapy. 1993 Sep-Oct;39(5):302-9. doi: 10.1159/000239141.

DOI:10.1159/000239141
PMID:8396526
Abstract

The in vitro inhibitory and bactericidal activities of daptomycin and reference antibiotics were determined by serial macrobroth dilution for 23 gentamicin-susceptible (MIC: < 2,000 mg/l) and 21 high-level-gentamicin-resistant (HLGR) Enterococcus faecalis, Enterococcus faecium, and Enterococcus avium isolates. The activities of daptomycin, vancomycin, and teicoplanin were independent of the gentamicin susceptibility profile and species tested. For all the isolates, the inhibitory activity of daptomycin (MIC90: 2 mg/l) was comparable to vancomycin (MIC90: 2 mg/l), but less than that of teicoplanin (MIC90: 0.5 mg/l). Daptomycin demonstrated excellent bactericidal activity against all enterococci tested (MBC90: 8 mg/l). In contrast, all microorganisms were tolerant to vancomycin and teicoplanin. Ampicillin and ciprofloxacin MICs and MBCs were dependent on enterococcal gentamicin resistance profile and species, with MICs and MBCs that ranged between 1 and > 64 mg/l. By time-kill curves, the combination of daptomycin plus ampicillin demonstrated synergistic bactericidal activity against gentamicin-susceptible and HLGR E. faecalis. Daptomycin, singly and in combination, may be useful in treating enterococcal infections, including those caused by HLGR microorganisms.

摘要

采用系列肉汤稀释法测定了达托霉素及对照抗生素对23株庆大霉素敏感(MIC:<2000mg/L)和21株高水平庆大霉素耐药(HLGR)的粪肠球菌、屎肠球菌和鸟肠球菌分离株的体外抑制和杀菌活性。达托霉素、万古霉素和替考拉宁的活性与庆大霉素敏感性谱及所测试的菌种无关。对于所有分离株,达托霉素的抑制活性(MIC90:2mg/L)与万古霉素(MIC90:2mg/L)相当,但低于替考拉宁(MIC90:0.5mg/L)。达托霉素对所有测试的肠球菌均表现出优异的杀菌活性(MBC90:8mg/L)。相比之下,所有微生物对万古霉素和替考拉宁均耐受。氨苄西林和环丙沙星的MIC和MBC取决于肠球菌的庆大霉素耐药谱及菌种,MIC和MBC范围在1至>64mg/L之间。通过时间杀菌曲线,达托霉素加氨苄西林的联合用药对庆大霉素敏感和HLGR粪肠球菌表现出协同杀菌活性。达托霉素单独使用或联合使用可能对治疗肠球菌感染有用,包括由HLGR微生物引起的感染。

相似文献

1
Comparison of in vitro inhibitory and bactericidal activities of daptomycin (LY 146032) and four reference antibiotics, singly and in combination, against gentamicin-susceptible and high-level-gentamicin-resistant enterococci.达托霉素(LY 146032)与四种对照抗生素单独及联合使用时,对庆大霉素敏感和高水平庆大霉素耐药肠球菌的体外抑制和杀菌活性比较。
Chemotherapy. 1993 Sep-Oct;39(5):302-9. doi: 10.1159/000239141.
2
Time-kill study and synergistic activity of cell-wall inhibitor antibiotics in combination with gentamicin against Enterococcus faecalis and Enterococcus faecium.细胞壁抑制剂抗生素与庆大霉素联合对粪肠球菌和屎肠球菌的时间杀菌研究及协同活性
Acta Microbiol Immunol Hung. 2011 Sep;58(3):219-26. doi: 10.1556/AMicr.58.2011.3.5.
3
Bactericidal activities of antibiotics against vancomycin-resistant Enterococcus faecium blood isolates and synergistic activities of combinations.抗生素对耐万古霉素屎肠球菌血流分离株的杀菌活性及联合用药的协同活性。
Antimicrob Agents Chemother. 1994 Jun;38(6):1225-9. doi: 10.1128/AAC.38.6.1225.
4
Dalbavancin is active in vitro against biofilms formed by dalbavancin-susceptible enterococci.达巴万星在体外对由对达巴万星敏感的肠球菌形成的生物膜具有活性。
Diagn Microbiol Infect Dis. 2018 Jan;90(1):58-63. doi: 10.1016/j.diagmicrobio.2017.09.015. Epub 2017 Sep 27.
5
In vitro evaluation of high-level, gentamicin-resistant enterococci isolated from bacteremic patients.对从菌血症患者中分离出的高水平庆大霉素耐药肠球菌的体外评估。
Pharmacotherapy. 1994 Jan-Feb;14(1):89-94. doi: 10.1002/j.1875-9114.1994.tb02791.x.
6
Unorthodox antibiotic combinations including ciprofloxacin against high-level gentamicin resistant enterococci.非传统抗生素组合,包括环丙沙星用于治疗对高水平庆大霉素耐药的肠球菌。
J Antimicrob Chemother. 1996 Apr;37(4):727-36. doi: 10.1093/jac/37.4.727.
7
Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.评价替加环素对金黄色葡萄球菌和对万古霉素、达托霉素或利奈唑胺敏感性降低的肠球菌的抗菌活性。
J Antimicrob Chemother. 2016 Jan;71(1):152-5. doi: 10.1093/jac/dkv302. Epub 2015 Oct 16.
8
Comparison of daptomycin, vancomycin, and ampicillin-gentamicin for treatment of experimental endocarditis caused by penicillin-resistant enterococci.达托霉素、万古霉素和氨苄西林-庆大霉素治疗耐青霉素肠球菌所致实验性心内膜炎的比较。
Antimicrob Agents Chemother. 1992 Sep;36(9):1864-9. doi: 10.1128/AAC.36.9.1864.
9
Serum bactericidal activities of high-dose daptomycin with and without coadministration of gentamicin against isolates of Staphylococcus aureus and Enterococcus species.高剂量达托霉素联合或不联合庆大霉素对金黄色葡萄球菌和肠球菌分离株的血清杀菌活性。
Antimicrob Agents Chemother. 2006 Nov;50(11):3529-34. doi: 10.1128/AAC.00290-06.
10
[Antibiotic susceptibility analysis of Enterococcus spp. isolated from urine].[从尿液中分离出的肠球菌属的抗生素敏感性分析]
Przegl Lek. 2004;61(5):473-6.

引用本文的文献

1
Identification of DraRS in , a Two-Component Regulatory System That Responds to Lipid II-Interacting Antibiotics.鉴定 中的 DraRS,这是一个双组份调控系统,对与脂质 II 相互作用的抗生素有响应。
J Bacteriol. 2023 Oct 26;205(10):e0016423. doi: 10.1128/jb.00164-23. Epub 2023 Jul 13.
2
HexSDF Is Required for Synthesis of a Novel Glycolipid That Mediates Daptomycin and Bacitracin Resistance in C. difficile.HexSDF 对于新型糖脂的合成是必需的,这种糖脂介导艰难梭菌对达托霉素和杆菌肽的耐药性。
mBio. 2023 Apr 25;14(2):e0339722. doi: 10.1128/mbio.03397-22. Epub 2023 Feb 14.
3
Activity of daptomycin with or without 25 percent ethanol compared to combinations of minocycline, EDTA, and 25 percent ethanol against methicillin-resistant Staphylococcus aureus isolates embedded in biofilm.
比较 25%乙醇联合达托霉素与米诺环素、EDTA 和 25%乙醇联合应用对生物膜中耐甲氧西林金黄色葡萄球菌的活性。
Antimicrob Agents Chemother. 2013 Apr;57(4):1998-2000. doi: 10.1128/AAC.01129-12. Epub 2013 Feb 12.
4
Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians.对临床医生而言,达托霉素中介粪肠球菌:一种新出现的挑战。
Clin Infect Dis. 2011 Jan 15;52(2):228-34. doi: 10.1093/cid/ciq113.
5
Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients.达托霉素治疗中性粒细胞减少患者的耐万古霉素屎肠球菌菌血症
J Infect. 2007 Jun;54(6):567-71. doi: 10.1016/j.jinf.2006.11.007. Epub 2006 Dec 26.
6
In vitro activities of a new lipopeptide, HMR 1043, against susceptible and resistant gram-positive isolates.新型脂肽HMR 1043对敏感及耐药革兰氏阳性菌分离株的体外活性
Antimicrob Agents Chemother. 2003 Sep;47(9):3025-9. doi: 10.1128/AAC.47.9.3025-3029.2003.
7
Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects.每日一次递增剂量给药于健康受试者后达托霉素的药代动力学和安全性。
Antimicrob Agents Chemother. 2003 Apr;47(4):1318-23. doi: 10.1128/AAC.47.4.1318-1323.2003.
8
Resistance studies with daptomycin.达托霉素的耐药性研究。
Antimicrob Agents Chemother. 2001 Jun;45(6):1799-802. doi: 10.1128/AAC.45.6.1799-1802.2001.
9
Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection.达托霉素在金黄色葡萄球菌感染小鼠大腿模型中的药效学
Antimicrob Agents Chemother. 2001 Mar;45(3):845-51. doi: 10.1128/AAC.45.3.845-851.2001.